An autologous preparation substantially red blood cell-free and neutrophil-depleted, comprising: a) Peripheral blood mononuclear cells (PBMNCs), b) Dimethylsulfoxide (DMSO) in concentrations comprised between 0.3% and 1.3% (v/v), c) Autologous platelet-enriched plasma, having a platelet concentration comprised between 700,000 platelets/μL and 1,200,000 platelets/μL; or platelet concentrate (B'), having a platelet concentration comprised between 7,000,000 platelets/μL and 12,000,000 platelets/μL, said autologous preparation being obtained with a process comprising the following steps: i) Obtaining, by treating a blood sample taken from the patient, autologous PBMNCs and platelet-enriched plasma or platelet concentrate (B'), respectively; ii) Adding DMSO to the PBMNCs obtained at step (i), at a concentration comprised between 3% and 5% (v/v) dissolved in a portion of platelet-enriched plasma or platelet concentrate (B') prepared in step i) and obtaining an autologous concentrate; iii) Freezing the autologous concentrate of item ii) and the autologous platelet-enriched plasma or platelet concentrate (B') as obtained at step i); iv) Sending the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of step iii) to the desired health care centre; v) Thawing, upon use, the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of item iv), vi) Diluting, 7 to 10 times, the volume of thawed autologous concentrate with thawed autologous plasma or thawed platelet concentrate (B') and obtaining the autologous preparation, wherein said autologous concentrate comprises mononuclear cells (PBMNCs), is red blood cell-free, neutrophil-depleted and comprises dimethylsulfoxide (DMSO) at a concentration comprised between 3vol% and 5vol% based on the volume of autologous concentrate. a) Peripheral blood mononuclear cells (PBMNCs), b) Dimethylsulfoxide (DMSO) in concentrations comprised between 0.3% and 1.3% (v/v), c) Autologous platelet-enriched plasma, having a platelet concentration comprised between 700,000 platelets/μL and 1,200,000 platelets/μL; or platelet concentrate (B'), having a platelet concentration comprised between 7,000,000 platelets/μL and 12,000,000 platelets/μL, said autologous preparation being obtained with a process comprising the following steps: i) Obtaining, by treating a blood sample taken from the patient, autologous PBMNCs and platelet-enriched plasma or platelet concentrate (B'), respectively; ii) Adding DMSO to the PBMNCs obtained at step (i), at a concentration comprised between 3% and 5% (v/v) dissolved in a portion of platelet-enriched plasma or platelet concentrate (B') prepared in step i) and obtaining an autologous concentrate; iii) Freezing the autologous concentrate of item ii) and the autologous platelet-enriched plasma or platelet concentrate (B') as obtained at step i); iv) Sending the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of step iii) to the desired health care centre; v) Thawing, upon use, the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of item iv), vi) Diluting, 7 to 10 times, the volume of thawed autologous concentrate with thawed autologous plasma or thawed platelet concentrate (B') and obtaining the autologous preparation, i) Obtaining, by treating a blood sample taken from the patient, autologous PBMNCs and platelet-enriched plasma or platelet concentrate (B'), respectively; ii) Adding DMSO to the PBMNCs obtained at step (i), at a concentration comprised between 3% and 5% (v/v) dissolved in a portion of platelet-enriched plasma or platelet concentrate (B') prepared in step i) and obtaining an autologous concentrate; iii) Freezing the autologous concentrate of item ii) and the autologous platelet-enriched plasma or platelet concentrate (B') as obtained at step i); iv) Sending the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of step iii) to the desired health care centre; v) Thawing, upon use, the autologous concentrate and the autologous platelet-enriched plasma or platelet concentrate (B') of item iv), vi) Diluting, 7 to 10 times, the volume of thawed autologous concentrate with thawed autologous plasma or thawed platelet concentrate (B') and obtaining the autologous preparation,